Categories
Tag: LRRK2
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution | Molecular Neurodegeneration
Single nucleus RNA-seq reveals cell type heterogeneity in human SNpc We sampled SNpc from post-mortem human brains of 15 sporadic Parkinson’s disease (PD) patients and 14 Control individuals (see Supplementary Table 1 for full pathology reports). Using a 10X Genomics Chromium platform, we performed single nucleus RNA-seq (snRNA-seq) on more than…
could it be a cure?
When CASGEVY, the first CRISPR-based therapy, was approved by the FDA in December, it gave CRISPR technology the validation it needed. Any promise it had held before that moment was simply investigational. In this case, the approval of CASGEVY was granted for the treatment of two blood disorders – sickle…
Formononetin | FGFR2 inhibitor | Axon 4067
All All Products Enzymes Receptors Ion Channels Research Areas Oxidoreductases Transferases Lyases Isomerases Ligases Nuclear Receptors Ligand-gated ATP-Sensitive Angiogenesis Apoptosis Cardiovascular Cell Cycle Regulation Cell Signaling & Oncology CNS Diabetes & Metabolism Epigenetics Immunology Miscellaneous Pain & Inflammation Stem Cell Oxidases MAO Cys-loop, cationic Cis-Trans Isomerase CypA DNA Topoisomerase Synthetases…
Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer’s disease | Cellular & Molecular Biology Letters
Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med. 2012;2(5): a006148. Article PubMed PubMed Central Google Scholar van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005;76(suppl 5):v2-7. Article PubMed PubMed Central …
2023-11-07 | NDAQ:ARVN | Press Release
– Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of 11.1 months in patients with AR…
When Glia Meet Induced Pluripotent Stem Cells (iPSCs)
Abstract The importance of glial cells, mainly astrocytes, oligodendrocytes, and microglia, in the central nervous system (CNS) has been increasingly appreciated. Recent advances have demonstrated the diversity of glial cells and their contribution to human CNS development, normal CNS functions, and disease progression. The uniqueness of human glial cells is…
New Potential Biomarker for Parkinson’s Disease: A Fresh Perspective
Researchers at Duke University have made an intriguing discovery in their investigation of mitochondrial DNA (mtDNA) as a potential biomarker for Parkinson’s disease. This breakthrough offers a new approach to measuring disease progression and identifying individuals at risk of developing Parkinson’s. Mitochondria, the energy powerhouses of our cells, have their…
A new potential biomarker for Parkinson’s
Researchers at Duke University have recently presented data on a new potential biomarker for Parkinson’s that could be useful in clinical trials targeting the LRRK2 gene in people with Parkinson’s. Human DNA contains all of our genetic information, with the instructions needed for our bodies to develop and function. DNA…
Expanding causal genes for Parkinson’s disease via multi-omics analysis
Proteins causally associated with PD in the brain MR analysis of brain dorsolateral prefrontal cortex (dlPFC) pQTLs identified six genetically determined significant proteins on PD after multiple testing corrections (P < 8.55E-05 (0.05/585)). Specifically, the increased abundance of 3 proteins was significantly associated with an increased risk of PD, including GPNMB (OR:1.464,…
Integrative single-nucleus multi-omics analysis prioritizes candidate cis and trans regulatory networks and their target genes in Alzheimer’s disease brains | Cell & Bioscience
Lo MT, Kauppi K, Fan CC, Sanyal N, Reas ET, Sundar VS, Lee WC, Desikan RS, McEvoy LK, Chen CH, Alzheimer’s Disease Genetics, C. Identification of genetic heterogeneity of Alzheimer’s disease across age. Neurobiol Aging. 2019;84(243):e241-243. doi.org/10.1016/j.neurobiolaging.2019.02.022. Article Google Scholar Nacmias B, Bagnoli S, Piaceri I, Sorbi S. Genetic heterogeneity…
Study on potential differentially expressed genes in idiopathic pulmonary fibrosis by bioinformatics and next generation sequencing data analysis
Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with reduced quality of life and earlier mortality, but its pathogenesis and key genes are still unclear. In this investigation, bioinformatics was used to deeply analyze the pathogenesis of IPF and related key genes, so as to investigate the…
Molecular basis for maternal inheritance of human mitochondrial DNA
Ankel-Simons, F. & Cummins, J. M. Misconceptions about mitochondria and mammalian fertilization: implications for theories on human evolution. Proc. Natl Acad. Sci. USA 93, 13859–13863 (1996). Article CAS PubMed PubMed Central Google Scholar Wallace, D. C. Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine….
The 5 Groundbreaking Advances In Biotechnology And Genetics
Unprecedented strides in biotechnology and genetics have radically transformed the scientific landscape. These advancements, notably CRISPR-Cas9 gene editing, gene therapy breakthroughs, emergence of personalized medicine, exploration of synthetic biology and novel gene-editing techniques, signify a revolutionary era in science with far-reaching implications. This article seeks to illuminate these pioneering developments…
2024 Breakthrough Prizes in Life Sciences
Eight scientists won the 2024 Breakthrough Prizes in Life Sciences. Breakthrough Prize Today (September 14) the Breakthrough Prize Foundation announced the recipients of the 2024 Breakthrough Prizes. Dubbed the “Oscars of Science,” the prestigious Breakthrough Prize recognizes outstanding contributions to science that advance our understanding and treatment of human disease….
Blood test may help with early diagnosis of Parkinson’s, before symptoms start | Study: Early diagnostic blood test assesses damage to mitochondrial DNA
A new blood test that assesses damage on a particular type of DNA may help in the early diagnosis of Parkinson’s disease, before symptoms start, a new study reports. “Currently, Parkinson’s disease is diagnosed largely based on clinical symptoms after significant neurological damage has already occurred,” Laurie Sanders, PhD, an…
Study: Quantitative detection of mitochondrial DNA damage using PCR method for Parkinson’s disease detection
More IVD industry news All in the [In Vitro Diagnostics Newsletter] APP An international team of researchers has developed a PCR-based assay to detect mitochondrial DNA (mtDNA) damage in blood, an indicator of Parkinson’s disease. The test, they say, could help diagnose the disease before a patient’s nervous system is…
New blood test detects key indicator of Parkinson’s disease
Blood test that detects Parkinson’s disease could establish a way to help diagnose the debilitating condition before damage to the nervous system worsens. A new blood-based diagnostic test could be a major advancement for the treatment of Parkinson’s, a disease that afflicts 10 million people worldwide and is the second-most…
New blood test pinpoints Parkinson’s disease through mitochondrial DNA damage
In a recent study published in the journal Science Translational Medicine, researchers investigate the potential of mitochondrial deoxyribonucleic acid (mtDNA) injury as a serological marker for Parkinson’s disease (PD) using the novel Mito DNADX test. Study: A blood-based marker of mitochondrial DNA damage in Parkinson’s disease. Image Credit: Kateryna Kon / Shutterstock.com What…
Mitochondrial DNA Damage May Serve as Biomarker of Parkinson’s Disease
NEW YORK — An international team of researchers has developed a PCR-based assay to detect mitochondrial DNA (mtDNA) damage in blood, an indicator of Parkinson’s disease. The test may help diagnose the condition before the nervous system of patients is excessively damaged, they said, and could be used to measure…
Parkinson’s Disease Blood Test Detects Mitochondrial DNA Damage
Researchers headed by a team at Duke University School of Medicine have developed a blood test that detects Parkinson’s disease, potentially establishing a way to help diagnose the condition before nervous system damage worsens. Assessed on blood samples from patients with Parkinson’s disease, the PCR-based assay (Mito DNADX) identifies mitochondrial…
The cGAS-STING-YY1 axis accelerates progression of neurodegeneration in a mouse model of Parkinson’s disease via LCN2-dependent astrocyte senescence
doi: 10.1038/s41418-023-01216-y. Online ahead of print. Affiliations Expand Affiliations 1 Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu, 211166, PR China. 2 Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu, 211166, PR China. drh@njmu.edu.cn….
CRISPR/Cas9 generation of knock-out iPSCs
May 23, 2023 MANUSCRIPT CITATION: Dou D, Smith EM, Evans CS, Boecker CA, Holzbaur EL, Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes. Cell reports 42(5). doi: 10.1016/j.celrep.2023.112448 License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License,…
iNeuron differentiation from human iPSCs
Boecker, C.A., and Holzbaur, E.L.F. (2021). Hyperactive LRRK2 kinase impairs the trafficking of axonal autophagosomes. Autophagy 00, 1–3. Boecker, C.A., Olenick, M.A., Gallagher, E.R., Ward, M.E., and Holzbaur, E.L.F. (2020). ToolBox: Live Imaging of intracellular organelle transport in induced pluripotent stem cell‐derived neurons. Traffic 21, 138–155. Fernandopulle, M.S., Prestil, R.,…
2023-08-08 | NDAQ:ARVN | Press Release
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2- metastatic breast cancer – – Interim data from Phase 1/2 dose escalation and expansion trial with ARV-766 shows promising signals…
Transcriptome sequencing reveals circRNA expression profile in Parkinson’s disease-like mice after aerobic exercise
. 2022 Mar 21;46(3):227-238. doi: 10.55730/1300-0152.2611. eCollection 2022. Affiliations Expand Affiliation 1 The First Affiliated Hospital of Hainan Medical College, Hainan, China. Item in Clipboard Tianlun Fan et al. Turk J Biol. 2022. Show details Display options Display options Format AbstractPubMedPMID . 2022 Mar 21;46(3):227-238. doi: 10.55730/1300-0152.2611. eCollection 2022. Affiliation 1…
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. However, that may have hit a peak as traffic started to unwind in June 2023 as ChatGPT traffic fell off for the first time since its launch. AI is…
DNA Sequencing Market to Surpass US$ 14,755.5 Million by 2030, Says Coherent Market Insights (CMI)
CMI Next-Gen DNA Sequencing Solutions: Empowering Precision Medicine & Genetic Research for Advancements in Healthcare & Biotechnology Burlingame, June 07, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, Global DNA Sequencing Market is estimated to be valued at US$ 6,802.2 million in 2023 and is expected to exhibit a CAGR…
DNA Sequencing Market to Surpass US$ 14,755.5 Million by
Burlingame, June 07, 2023 (GLOBE NEWSWIRE) — According to Coherent Market Insights, Global DNA Sequencing Market is estimated to be valued at US$ 6,802.2 million in 2023 and is expected to exhibit a CAGR of 11.7% during the forecast period (2023-2030). Analysts’ Views on Global DNA Sequencing Market: Rising demand for…
Superior Cognition in the Oldest-Old; Novel MS Pathway; What Links Amyloid and Tau?
Superior global cognition in the oldest-old was associated with resistance to neurodegenerative pathologies, autopsy data showed. (Journal of Alzheimer’s Disease) Brain network models showed that people with higher intelligence scores took more time to solve difficult problems, and that slower solvers had higher average functional connectivity. (Nature Communications) The novel…
Biogen and Denali Terminate Phase 3 LIGHTHOUSE Study of BIIB122 in LRRK2-related Parkinson Disease
Samantha B. Haeberlein, PhD Biogen and Denali have announced that they are discontinuing a portion of the clinical development program for BIIB122 (also known as DNL151), an investigational small molecule inhibitor of LRRK2 in development for the treatment of Parkinson disease (PD). As a result of this decision, the phase…
Parkinson’s cure ‘inevitable’ after biomarker breakthrough
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced what it says is the ‘most significant breakthrough yet’ in the search for a Parkinson’s biomarker: a biological test for Parkinson’s disease. The test demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement…
The IPDGC/GP2 Hackathon – an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data
GWAS-level and post-GWAS analyses GWAS of PD have nominated 90 independent risk signals in individuals of European ancestry, explaining ~16–36% of the heritable risk7, as well as two additional risk signals in Asian populations8. Typically, published GWAS are accompanied by various follow-up analyses, but performing these analyses is not always…
Identification of novel prognostic targets in coronary artery disease and related complications using bioinformatics and next generation sequencing data analysis
Abstract Coronary artery disease (CAD) is the most common cardiovascular disorder and the leading cause of heart-related deaths in world. Increasing molecular targets have been discovered for CAD and CAD – related complications prognosis and therapy. However, there is still an urgent need to identify novel biomarkers. Therefore, we evaluated…
New Stem Cell-Derived Neuron Datasets Available
15 Feb 2023 It’s time to add two new stem cell databases to the neurological disease research toolbox. For one, Clive Svendsen at Cedars-Sinai Medical Center, Los Angeles, and colleagues at Answer ALS led a team of scientists that created motor neurons from induced pluripotent stem cells derived from 92…
Immunofluorescence-based assay to assess LRRK2 recruitment by Rab29
Feb 01, 2023 DOI: dx.doi.org/10.17504/protocols.io.bp2l69r8klqe/v1 Protocol Citation: Francesca Tonelli 2023. Immunofluorescence-based assay to assess LRRK2 recruitment by Rab29. protocols.io dx.doi.org/10.17504/protocols.io.bp2l69r8klqe/v1 License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited…
2022, a Year in Review
15 Jan 2023 Part 1 of 2The year 2022 was a turning point in Alzheimer’s research. It began with the Aduhelm debacle fresh on people’s mind. It ended with reassurance that amyloid removal indeed helps people with the disease, when lecanemab’s Phase 3 data showed a slowing of cognitive decline….
Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential
Weisman, D. & McKeith, I. Dementia with Lewy Bodies. Semin. Neurol. 27, 042–047 (2007). Article Google Scholar Foguem, C. & Manckoundia, P. Lewy Body Disease: Clinical and Pathological “Overlap Syndrome” Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease). Curr. Neurol. Neurosci. Rep. 2018 18:5 18, 1–9 (2018). CAS Google Scholar …
Dosing Begins for LIGHTHOUSE, Parkinson’s Clinical Trial of BIIB122
Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up to 400 patients…